- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00804661
Sleep in Patients With Cystic Fibrosis (Sommeil)
Predictors of Nocturnal Hypoventilation in Patients With Cystic Fibrosis
Study Overview
Detailed Description
Background In patients with cystic fibrosis (CF), respiratory disease is characterised by a progressive and ineluctable decline in lung function. Sleep-disordered breathing may occur at an early stage of lung disease and may impair quality of life. Oxygen therapy or noninvasive positive pressure ventilation may improve nocturnal hypoxemia and hypercapnia.Risk factors for nocturnal hypercapnia or hypoxemia are not well identified in patients with CF.
Type of study : prospective, transversal, open
Methods :
During the annual check up, a sleep study will be performed with a nocturnal recording of a least 6 hours of pulse oximetry (SaO2) and transcutaneous carbon dioxide (PtcCO2) by the SENTEC device and wrist movements by means of actigraphy. The results of the sleep study will be correlated to·
- clinical scores which evaluate sleep quality (such as the PITTSBURG Sleep Quality Score).·
- respiratory function parameters : lung volumes, forced expiratory of the respiratory muscles: maximal inspiratory and expiratory pressures and the sniff nasal inspiratory pressure.·
- nutritional state with the body mass index z-score·
- the presence of arterial pulmonary hypertension on an echocardiography·
- infectious status (colonisation by Staphylococcus aureus or Pseudomonas aeruginosa) and the CFTR genotype.
Expected results This study should be able to document abnormal nocturnal gas exchange and sleep-disordered breathing in patients with CF in a stable state. The identification of parameters associated with nocturnal hypoventilation and/or poor sleep quality will help to screen those patients who will need a sleep study and treatment such as oxygen therapy or noninvasive positive pressure ventilation.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75012
- AP-HP, Armand Trousseau hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- children > 8 years and adults with CF
- in a stable state (no acute respiratory exacerbation since one month or patient finishing an antibiotic course)
- able to perform reproducible forced expiratory flows
- having a forced expiratory volume in one second ≤ 60% predicted value
- who accepts to perform a sleep study in the hospital during one night
- written agreement to participate to the study
Exclusion Criteria:
- acute respiratory exacerbation in the previous month or patient who has not finished an antibiotic course
- Inability or impossibility to perform reproducible forced expiratory flows (pneumothorax during the previous year and/or without surgery)
- having a forced expiratory volume in one second > 60% predicted value
- refusal or impossibility to perform a sleep study in the hospital during one night
- patients receiving long term oxygen therapy or noninvasive positive pressure ventilation
- no social security
- impossibility of a medical examination
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
1
Children and adults with cystic fibrosis
|
Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To determine clinical and functional parameters associated with nocturnal hypoventilation defined by· - A mean transcutaneous carbon dioxide pressure (PtcCO2) ≥ 45 mm Hg· - And/or a maximal PtcCO2 ≥ 55 mm Hg· - And/or a PtcCO2 ≥ 45 mm Hg during ≥ 50%
Time Frame: At the inclusion visit
|
At the inclusion visit
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To determine clinical and functional parameters associated with- sleep -disordered breathing defined by the presence of arousals on actigraphy (Actiwatch™) in children and adults with CF - nocturnal hypoxemia defined by -- a mean pulse oximetry (SaO2)
Time Frame: At the inclusion visit
|
At the inclusion visit
|
Collaborators and Investigators
Investigators
- Principal Investigator: Brigitte Fauroux, MD, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- P070202
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.